<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02714816</url>
  </required_header>
  <id_info>
    <org_study_id>MGT005</org_study_id>
    <nct_id>NCT02714816</nct_id>
  </id_info>
  <brief_title>Natural History Study of Patients With Leber Congenital Amaurosis Associated With Mutations in RPE65</brief_title>
  <official_title>Natural History Study of Patients With Leber Congenital Amaurosis Associated With Mutations in RPE65</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MeiraGTx UK II Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MeiraGTx UK II Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MGT005 is a natural history study to collect longitudinal prospective data from patients with&#xD;
      Leber Congenital Amaurosis associated with defects in RPE65.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Leber Congenital Amaurosis (LCA) is a diagnosis for a group of severe, autosomal recessively&#xD;
      inherited rod - cone dystrophies that typically result in complete visual loss in the third&#xD;
      or fourth decade of life. One form, LCA2, is caused by a mutation in the gene encoding RPE56,&#xD;
      an RPE-specific 65-kDa isomerase. Non-functional RPE65 results in photoreceptor cells that&#xD;
      are unable to respond to light resulting in these patients being visually impaired.&#xD;
&#xD;
      In preparation for human clinical trials, a detailed prospective phenotypic study will be&#xD;
      undertaken to investigate the natural history of RPE65-LCA. Such a study will help identify&#xD;
      suitable patients for therapeutic intervention. Furthermore through greater phenotyping an&#xD;
      optimal window for intervention and specific parameters to help quantify effect and identify&#xD;
      clinical end points may have been ascertained .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of retinal structure and function</measure>
    <time_frame>6 years</time_frame>
    <description>Retinal structure will be analysed using Adaptive optics and SD-OCT and Fundal autofluorescence. This will be correlated with assessment of visual acuity, psychophysical visual assessment, visual mobility, retinal sensitivity and visual fields</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaires</measure>
    <time_frame>6 years</time_frame>
    <description>Assessment of Visual impairment using appropriate, validated questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal Sensitivity</measure>
    <time_frame>6 years</time_frame>
    <description>To be assessed in Microperimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal Structural analysis</measure>
    <time_frame>6 years</time_frame>
    <description>Retinal Structure analysis with Adaptive Optics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fundal Autofluorescence</measure>
    <time_frame>6 years</time_frame>
    <description>Presence or Absence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Visual Fields</measure>
    <time_frame>6 years</time_frame>
    <description>Assessment of Visual Fields with analysis of hill of vision</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Leber Congenital Amaurosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with RPE65-LCA condition&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with RPE65 associated retinal dystrophy&#xD;
&#xD;
          -  Minimum subject age of 3 years&#xD;
&#xD;
          -  Able to give consent/parent or guardian able to give consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unable or unwilling to undertake consent or clinical testing&#xD;
&#xD;
          -  Have received a gene therapy treatment in both eyes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Michealides, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCL/Moorfileds</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MeiraGTx UK II Ltd, MSc</last_name>
    <phone>+44 (0)20 3866 4320</phone>
    <email>ocularinfo@meiragtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kellogg Eye Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>MI 48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrienne Chen</last_name>
      <phone>734-232-9167</phone>
      <email>KelloggResearch@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Dr Jayasundera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Habiba Sultana</last_name>
      <phone>020 7566 2821</phone>
      <email>habiba.sultana@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Michel Michealides, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 8, 2016</study_first_submitted>
  <study_first_submitted_qc>March 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2016</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blindness</mesh_term>
    <mesh_term>Leber Congenital Amaurosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

